10-K: AptarGroup Reports 3% Sales Growth in 2024, Driven by Pharma and Strategic Acquisitions

AptarGroup's 2024 annual report reveals a 3% increase in both reported and core sales, reaching $3.58 billion, fueled by favorable product mix and volume growth.

Summary

• AptarGroup's 2024 net sales increased by 3% to $3.58 billion.
• Core sales, excluding acquisitions and currency effects, also grew by 3%.
• Diluted earnings per share grew by 30%, while adjusted earnings per share increased by 18%.
• Net income rose by 32% to $375 million.
• Net cash provided by operations increased by 12%, and free cash flow increased by 40%.
• The Aptar Pharma segment accounted for approximately 46% of net sales and 67% of adjusted EBITDA.
• The Aptar Beauty segment represented 34% of net sales and 19% of adjusted EBITDA.
• The Aptar Closures segment accounted for 20% of net sales and 14% of adjusted EBITDA.
• In October 2024, Aptar acquired 40% of Goldrain for approximately $99 million.
• In March 2023, Aptar acquired iD SCENT and 80% of Gulf Closures.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with solid growth in sales and earnings, strategic acquisitions, and a commitment to sustainability. However, there are also some risks and challenges mentioned, such as economic conditions, competition, and foreign currency exposure, which temper the overall sentiment.

Positives

• Strong sales growth in the Aptar Pharma segment, particularly in prescription drugs and active material science solutions.
• Improved operational performance and cost management initiatives across all segments.
• Increased net cash provided by operations and free cash flow.
• Strategic acquisitions and partnerships to expand technology, geographic presence, and product offerings.
• Commitment to sustainability and environmentally friendly products.
• 31st consecutive year of paying an annually increasing dividend.

Negatives

• Aptar Beauty's sales decreased 3% due to lower tooling sales and difficult European comparisons.
• Increased interest expense due to debt refinancing at higher variable interest rates.
• Exposure to foreign currency translation risks.
• Potential for goodwill impairment if future business conditions deteriorate.
• Risk of customer consolidation leading to pricing pressures.

Risks

• Deterioration in economic conditions could adversely impact business and operating results.
• Geopolitical conditions, including trade disputes and acts of war, could disrupt operations and financial results.
• Increased global cybersecurity threats could pose a risk to operations.
• Strong global competition could lead to a decline in market share.
• Inability to adequately source materials, including those from a single supplier, could impact ability to deliver products.
• Global health crises, such as the COVID-19 pandemic, could adversely affect business.
• Government regulation on environmental matters could impact business.
• Interest rate volatility could increase borrowing costs.

Future Outlook

Aptar expects earnings per share for the first quarter of 2025, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition-related costs, to be in the range of $1.11 to $1.19 and this guidance is based on an effective tax rate range of 25% to 27%.

Management Comments

• Aptar is a global leader in the design and manufacturing of drug and consumer product dosing, dispensing and protection technologies.
• Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care, and home care.
• We seek to enhance our position as a leading global provider in drug and consumer dosing, dispensing and protection technologies to deliver increased value to our customers and stockholders through strategic focus and execution.

Industry Context

Aptar operates in highly competitive markets, facing competition from both privately and publicly held entities. The company's competitive advantages include innovation, quality, regulatory expertise, geographic diversity, and financial strength. The industry is seeing increased interest in sustainable packaging solutions, which Aptar is addressing through the use of PCR resin and recyclable products.

Comparison to Industry Standards

• The peer group used for performance comparison includes companies like Albemarle Corporation, Ashland Inc., Berry Global Group, Inc., Catalent, Inc., CCL Industries Inc., Enovis Corporation, ICU Medical, Inc., Ingredion Inc., International Flavors & Fragrances, Inc., McCormick & Company, Inc., Perrigo Company plc, Revvity, Inc., Sealed Air Corporation, Sensient Technologies Corporation, Silgan Holdings, Inc., Sonoco Products Company, Stericycle, Inc., STERIS plc, Teleflex Inc. and West Pharmaceutical Services, Inc.
• These companies compete with Aptar for market share, operate in similar industries (e.g., packaging, specialty chemicals, specialty materials), and provide similar intermediate products to similar end-use markets.
• The peer group companies are selected based on factors such as revenue, assets, invested capital, number of employees, market capitalization, geographic presence, and competition for senior executive talent.

Management Changes

Legal Proceedings

• The company is subject to a number of lawsuits and claims in the normal course of business.
• The company is subject to investigations, audits and other proceedings initiated by federal, state, international, national, provincial and local authorities, including regulatory agencies such as the FDA as a result of the products manufactured by our Aptar Pharma segment.

Related Party Transactions

• For the years ended December 31, 2024, 2023 and 2022, Aptar had purchases of $11.4 million, $14.3 million and $11.4 million, respectively, from BTY.
• As of December 31, 2024 and 2023, approximately $2.5 million and $1.8 million, respectively, was due to BTY and included in accounts payable, accrued and other liabilities on our Consolidated Balance Sheets.

Stakeholder Impact

• Shareholders: Continued dividend payments and share repurchases.
• Employees: Focus on talent development and leadership succession.
• Customers: Commitment to innovation and providing sustainable solutions.
• Suppliers: Emphasis on responsible sourcing and supply chain management.

Next Steps

• Continue to focus on organic growth with an added focus in high growth regions.
• Continue to focus on talent acquisition and development strategies.
• Continue to manage fixed costs and improve return on invested capital.
• Continue to focus on growing the Company through appropriate business acquisition opportunities as well as developing partnerships.

Key Dates

Keywords

AptarGroup, net sales, adjusted EBITDA, pharmaceutical packaging, dispensing systems, drug delivery, closures, beauty, acquisitions, sustainability